Randomized Comparison of Everolimus-Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery Disease in Patients With Diabetes Mellitus (ESSENCE-DIABETES): Results From the ESSENCE-DIABETES Trial
暂无分享,去创建一个
I. Seong | J. Chae | Seung‐Jung Park | S. Yun | Young-Hak Kim | H. Park | Duk‐Woo Park | Tae-Hyun Yang | Cheol-Whan Lee | Seung‐Whan Lee | Sang‐Gon Lee | S. Cheong | Jae-Sik Jang | Soo-Jin Kang | Won-Jang Kim | Seong-Wook Park | Y. Choi | Jae‐Hwan Lee | N. Lee | Y. Cho | W. Park | Si-Wan Choi | Kyoung-Ha Park | Seung-Jin Lee | D. Bang | Bong-Ki Lee | Hyun-Sook Kim | W. Shin | Jong-Young Lee | M. Hyon | Min-Kyu Kim | S. Her | Chang-Bum Park | Se‐Whan Lee | Keun Lee | C. Lee
[1] M. Jeong,et al. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. , 2011, Journal of the American College of Cardiology.
[2] G. Stone,et al. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). , 2010, Journal of the American College of Cardiology.
[3] P. Fitzgerald,et al. Comparison of everolimus- versus paclitaxel-eluting stents implanted in patients with diabetes mellitus as evaluated by three-dimensional intravascular ultrasound analysis. , 2010, The American journal of cardiology.
[4] Volker Klauss,et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. , 2010, The New England journal of medicine.
[5] Patrick W Serruys,et al. An everolimus‐eluting stent versus a paclitaxel‐eluting stent in small vessel coronary artery disease: A pooled analysis from the SPIRIT II and SPIRIT III trials , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[6] P. Fitzgerald,et al. SPIRIT III JAPAN versus SPIRIT III USA: a comparative intravascular ultrasound analysis of the everolimus-eluting stent. , 2010, The American journal of cardiology.
[7] Gregg W Stone,et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. , 2010, The New England journal of medicine.
[8] P. Smits,et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial , 2010, The Lancet.
[9] A. Kastrati,et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. , 2009, European heart journal.
[10] P. Serruys,et al. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry. , 2009, Journal of the American College of Cardiology.
[11] I. Seong,et al. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus 2-year clinical outcomes of the DES-DIABETES trial. , 2009, Journal of the American College of Cardiology.
[12] I. Seong,et al. A randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus. , 2008, Journal of the American College of Cardiology.
[13] P. Fitzgerald,et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. , 2008, JAMA.
[14] P. Serruys,et al. Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[15] F. Prati,et al. Head-to-Head Comparison of Sirolimus- and Paclitaxel-Eluting Stent in the Same Diabetic Patient With Multiple Coronary Artery Lesions , 2008, Diabetes Care.
[16] H. Drexler,et al. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. , 2007, Journal of the American College of Cardiology.
[17] Brett G. Sylvia,et al. Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. , 2007, The American journal of cardiology.
[18] C. Yancy,et al. Thrombosis in Coronary Drug-Eluting Stents: Report From the Meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7–8, 2006* , 2007, Circulation.
[19] P. Serruys,et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. , 2006, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[20] T. Ahn,et al. Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes , 2006, Heart.
[21] Seung‐Jung Park,et al. Impact of diabetes mellitus on angiographic and clinical outcomes in the drug-eluting stents era. , 2005, The American journal of cardiology.
[22] F. Fernández‐Avilés,et al. Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial , 2005, Circulation.
[23] A. Kastrati,et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. , 2005, The New England journal of medicine.
[24] G. Stone,et al. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. , 2005, Journal of the American College of Cardiology.
[25] G. Breithardt,et al. Relationship of Late Loss in Lumen Diameter to Coronary Restenosis in Sirolimus-Eluting Stents , 2005, Circulation.
[26] G. Stone,et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. , 1999, Circulation.
[27] M. Leon,et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. , 1997, Circulation.
[28] D. Faxon,et al. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. , 1996, Circulation.
[29] P. Jacobsen. Design and analysis of clinical trials. , 1988, Journal of dentistry.
[30] J. Ge,et al. Meta-analysis of five randomized clinical trials comparing sirolimus- versus paclitaxel-eluting stents in patients with diabetes mellitus. , 2010, The American journal of cardiology.
[31] S. Pocock,et al. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. , 2008, Journal of the American College of Cardiology.
[32] J. Mehilli,et al. Drug-eluting Stents in Diabetic Patients , 2006 .
[33] Jeff Lin,et al. Design and Analysis of Clinical Trials , 2006 .